Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cell genomics provider Geninus, today announce a strategic partnership to develop a patient stratification and prognostic platform for Non-Small Cell Lung Cancer (NSCLC).
Continue reading
Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today announced a strategic partnership in developing a patient identification and diagnostic platform for rare diseases.
Continue reading
Quarterly update on Scailyte’s progress towards its mission to save millions of lives.
Continue reading
ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming all competitor algorithms.
Continue reading
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day. Scailyte will present its pioneering AI-based platform for biomarker discovery from single-cell and clinical data to enable precision diagnostics in oncology, immunology and women’s health. Scailyte’s forward-thinking team will explain how they plan to unlock clinically relevant insights which will improve patient outcomes.
Continue reading
Q3 2020 update on Scailyte’s progress towards its mission to save millions of lives.
Continue reading
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus, indications and presenting the biomarker portfolio.
Continue reading
Today, Scailyte closed their pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, joined by 4FO ventures, a private investor, Hemex and Investiere. This pre-series A financing round will allow Scailyte to develop faster their assays in the rapid-emerging single-cell data technology field. The raised capital will be used to further build upon Scailyte’s biomarker and IVD pipeline and for the development of the first clinical applications using single-cell biomarkers.
Scailyte is honored to have investiere among their renowned investor base. The additional financing increases the opportunities for Scailyte to develop in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™.
“We are continuously developing and utilizing our data analytics platform ScaiVision™ for biomarker discovery from single-cell data” says Peter Nestorov, CEO of Scailyte AG. “The current version covers all aspects of processing, handling and interpreting single-cell proteomics data (mass and flow cytometry), as well as a core functionality for analysing single-cell transcriptomics data. This allows us to accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures, 4FO and HEMEX, we will continue to grow in the fast-emerging single-cell analysis field, enabling various clinical applications of single-cell data “.
“Scailyte has a strong product pipeline. It includes candidates for biomarkers for Endometriosis and CTCL with a market potential of several hundred million Francs for each of these diagnostics. Furthermore, Scailyte enjoys strong support in the medical expert community” says Susanne Schorsch, Investment Manager at investiere.
investiere provides exclusive access to start-up investments to qualified private and institutional investors. investiere is one of the most active startup investors in Switzerland, backed by business angels as well as ZKB with more than 90 investments.
Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning several national and international start-ups competitions and is the beneficiary of significant research grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial Intelligence, Software development, Finance, Marketing and Sales. Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™. ScaiVision™ offers best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery, and precision diagnostics. Besides developing its own in vitro diagnostic (IVD) applications, Scailyte also offers its biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.
The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised pattern recognition analysis of single-cell data. The performance and clinically relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t...
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow...
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better...
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel...
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel...
ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m...
Scailyte AG announces a strategic partnership with Sirona DX for AI-driven end-point specific single...
Watch Scailyte's webinar on "Supervised learning of disease-associated cell states and dynamics" wit...
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t...
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow...
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better...
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel...
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel...
ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m...
Scailyte AG announces a strategic partnership with Sirona DX for AI-driven end-point specific single...
Watch Scailyte's webinar on "Supervised learning of disease-associated cell states and dynamics" wit...
In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO of a start-up, a strong make it happen mentality, and the support of a smart and experienced team is crucial.
Continue reading
In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen describes how our understanding of biology is advancing thanks to technological progress. Scailyte is on a mission to save millions of lives by developing single-cell precision diagnostics.
Continue reading
